Nektar Therapeutics 10-Q quarterly reports

Nektar Therapeutics reported a reduced net loss in Q3 2025, driven by lower operating expenses, while advancing its lead immunotherapy candidates and securing significant capital.

Nektar Therapeutics reported a reduced quarterly net loss and positive Phase 2b data for rezpegaldesleukin, while securing significant capital post-period.

Nektar Therapeutics announces its Q1 2025 financial results, detailing a net loss of $50.88 million and highlighting the progress of its clinical programs, particularly rezpegaldesleukin.

Nektar Therapeutics' Q3 2024 report details financial results, strategic updates, and progress in clinical development programs, including the sale of its manufacturing facility.

Nektar Therapeutics' second quarter 2024 results reflect ongoing strategic reorganization and cost restructuring efforts, with a focus on advancing key drug candidates.

Nektar Therapeutics announced its first quarter 2024 financial results, emphasizing advancements in its rezpegaldesleukin and NKTR-255 clinical programs and strategic financial maneuvers.